Amit Oza
Princess Margaret Cancer Centre · University Health Network, Toronto · Princess Margaret Cancer Centre, UHN and Mt. Sinai Health System
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amit Oza as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:59 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06328491 · Erdafitinib in Metastatic Steroid-cell Ovarian CancerUniversity Health Network, Toronto · completed · Ovarian Cancer, Steroid Cell Tumor, Malignant · principal investigator
- N/ANCT06285500 · Umbrella Study for Single Patient Treatments in OncologyUniversity Health Network, Toronto · recruiting · Advanced Cancer, Rare Diseases · principal investigator
- N/ANCT06254781 · Luspatercept in Metastatic AGCT of the OvaryUniversity Health Network, Toronto · completed · Adult Granulosa Cell Tumor of the Ovary · principal investigator
- Ph2NCT04239014 · A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.AstraZeneca · withdrawn · Ovarian Cancer · principal investigator
- Ph2/Ph3NCT04159155 · A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerUniversity Health Network, Toronto · terminated · Endometrial Carcinoma, P53 Mutation, Serous Carcinoma · principal investigator
- Ph2NCT03480776 · ASA in Prevention of Ovarian Cancer (STICs and STONEs)Canadian Cancer Trials Group · active not recruiting · Ovarian Cancer Prevention · study chair
- N/ANCT03420118 · Study of Biomarkers in Gynecological CancersUniversity Health Network, Toronto · recruiting · Gynecologic Cancer · principal investigator
- N/ANCT03419689 · Study Looking at Biomarkers in Ovarian CancerUniversity Health Network, Toronto · recruiting · Gynecologic Cancer · principal investigator
- Ph2NCT03029403 · Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerUniversity Health Network, Toronto · active not recruiting · Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma · principal investigator
- N/ANCT02952521 · Ovarian Tumor Biopsies to Study Response to TreatmentsUniversity Health Network, Toronto · completed · Epithelial Ovarian Cancer · principal investigator
- N/ANCT02681237 · A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerUniversity Health Network, Toronto · completed · Ovarian Cancer · principal investigator
- Ph2NCT02489006 · A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerUniversity Health Network, Toronto · active not recruiting · Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment · principal investigator
- N/ANCT02489058 · A Study of Long-Term Responders on OlaparibUniversity Health Network, Toronto · completed · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer · principal investigator
- N/ANCT02341118 · Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.University Health Network, Toronto · terminated · Ovarian Cancer · principal investigator
- Ph2NCT02340611 · A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibUniversity Health Network, Toronto · completed · Ovarian Cancer · principal investigator
- N/ANCT02334761 · Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.University Health Network, Toronto · completed · Pathology · principal investigator
- Ph1NCT02185690 · A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the LungUniversity Health Network, Toronto · completed · Lungcancer · study director
- Ph2NCT01914510 · A Study of ENMD-2076 in Ovarian Clear Cell CancersUniversity Health Network, Toronto · completed · Ovarian Clear Cell Carcinoma · principal investigator
- Ph1NCT01198184 · Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Renal Cell Cancer · principal investigator
- Ph2NCT01175343 · RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma · principal investigator
- Ph1/Ph2NCT01083537 · Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel ObstructionUniversity Health Network, Toronto · terminated · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT01081951 · Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerAstraZeneca · active not recruiting · Ovarian Cancer · principal investigator
- Ph2NCT00607607 · A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial CancerCASI pharmaceuticals, Inc. · completed · Ovarian Cancer, Endometrial Cancer · principal investigator
- Ph1/Ph2NCT00510250 · A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical CancerUniversity Health Network, Toronto · completed · Cancer of the Cervix · principal investigator
- Ph1NCT00408655 · Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Endometrial Carcinoma · principal investigator
- Ph2NCT00390234 · Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaNational Cancer Institute (NCI) · completed · Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma · principal investigator
- Ph2NCT00301756 · Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential TumorsNational Cancer Institute (NCI) · completed · Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor · principal investigator
- Ph2NCT00096395 · Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian CancerNational Cancer Institute (NCI) · completed · Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer · principal investigator
- Ph2NCT00072176 · Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma · principal investigator
- Ph2NCT00032110 · Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal CancerNational Cancer Institute (NCI) · completed · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Princess Margaret Phase I Consorium (PMP1C)UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2016 to 2019 · $99,360 awarded in 2019Same name and institution; not confirmed by an ID
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS26120110003 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2011 to 2015 · $1,116,421 awarded in 2015Same name and institution; not confirmed by an ID
- Early Therapeutics Development with Phase II EmphasisN01CM62203- · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2007 to 2011 · $693,681 awarded in 2011Grant number is on one of their registry trials
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622003N01CM622003 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Princess Margaret Hospital Phase I ConsortiumU01CA132123 · NCI · UNIVERSITY HEALTH NETWORK · PI Lillian L Siu · fiscal years 2008 to 2013Named on NCT01198184
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:59 UTC. The ranking covers the 200 most relevant of 200 PubMed records, and a shared surname and initials can bring in a namesake. All 200 on PubMed
- 2,326 citationsRCR 81.5
- 2,017 citationsRCR 64.0
- A phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med · 20111,749 citationsRCR 45.0
- 1,432 citationsRCR 46.8
- 1,419 citationsRCR 44.3
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.Lancet · 20141,390 citationsRCR 53.8
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol · 2017974 citationsRCR 29.9
- 916 citationsRCR 21.2
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol · 2015683 citationsRCR 21.5
- 540 citationsRCR 13.1